Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

Representing Georgia's life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation.

In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies.

GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities.

As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia's life sciences community has a voice in the policymaking process.

Read Georgia Life Sciences' full comments to CMS (click here).

< Older Post

Newer Post >